Format

Send to:

Choose Destination
See comment in PubMed Commons below
Diabetes Care. 2010 Jun;33(6):1193-9. doi: 10.2337/dc09-1888. Epub 2010 Mar 23.

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

Author information

  • 1Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. rli2@cdc.gov

Abstract

OBJECTIVE:

To assess the long-term cost-effectiveness of aspirin use among adults aged >or=40 years with newly diagnosed type 2 diabetes.

RESEARCH DESIGN AND METHODS:

We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death.

RESULTS:

Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios.

CONCLUSIONS:

Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.

PMID:
20332350
[PubMed - indexed for MEDLINE]
PMCID:
PMC2875422
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk